Free Trial
OTCMKTS:PARD

Poniard Pharmaceuticals (PARD) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free PARD Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
7 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartFinancials

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

PARD Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive PARD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poniard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/23/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:PARD
CUSIP
N/A
CIK
755806
Web
www.poniard.com
Phone
(206) 281-7001
Fax
650-583-3789
Employees
7
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
1.14
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Robert F. Caspari (Age 76)
    Exec. Officer
  • Dr. Paul G. Abrams
    Exec. Officer

Key Competitors

View All Competitors

PARD Stock Analysis - Frequently Asked Questions

How do I buy shares of Poniard Pharmaceuticals?

Shares of PARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PARD) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
SHOCKING Crypto Leak…
Crypto 101 Media
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!
American Alternative
How to camouflage a factory of 53,000 workers
Stansberry Research
Man Who Predicted 2008: “This Will be Worse.”
Altimetry